22 07, 2021 Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Useadmin2021-07-21T15:56:56-04:00July 22nd, 2021|Press Release| Read More
29 06, 2021 Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisiniclineadmin2021-06-28T14:56:54-04:00June 29th, 2021|Press Release| Read More
3 06, 2021 Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addictionadmin2021-06-02T19:52:19-04:00June 3rd, 2021|Press Release| Read More
2 06, 2021 Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conferenceadmin2021-05-29T14:00:41-04:00June 2nd, 2021|Press Release| Read More
27 05, 2021 Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Sharesadmin2021-05-27T14:05:31-04:00May 27th, 2021|Press Release| Read More
25 05, 2021 Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offeringadmin2021-05-25T00:08:31-04:00May 25th, 2021|Press Release| Read More